Pancreatic cancer cells resistance to gemcitabine: The role of MUC4 mucin

British Journal of Cancer

Volumn 101, Issue 7, 2009, Pages 1155-1161

  Bafna, S ^a   Kaur, S ^a   Momi, N ^a   Batra, S K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; MUC4; Pancreatic cancer; Resistance

Indexed keywords

CASPASE 9; CD18 ANTIGEN; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 4; PROTEIN BAD;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOSOL; DNA FRAGMENTATION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; STAINING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; CYTOSOL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MUCIN-4; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 70349653064     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605285     Document Type: Article

References (23)

1. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP, Batra SK (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 7: 4033-4040 (Pubitemid 34044624)
2. Bafna S, Singh AP, Moniaux N, Eudy JD, Meza JL, Batra SK (2008) MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res 68: 9231-9238
3. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909
4. Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK (2008) MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 68: 2065-2070
5. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra SK (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 5: 309-320 (Pubitemid 46706993)
6. El-Rayes BF, Philip PA (2003) A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol 1: 430-434
7. Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97: 453-457
8. Keighley MR (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18(Suppl 3): 7-30
9. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S, Weichselbaum R, Nalin C, Kufe D (1997) Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94: 6939-6942 (Pubitemid 27281969)
10. Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert JP, Batra SK (2007) Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer 97: 345-357 (Pubitemid 47196741)
11. Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482
12. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL (2004) Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 6: 119-125
13. Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99: 783-791 (Pubitemid 34575694)
14. Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, Kharbanda S, Kufe D (2006) MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 25: 3774-3783 (Pubitemid 44300263)
15. Raina D, Kharbanda S, Kufe D (2004) The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 279: 20607-20612 (Pubitemid 38656454)
16. Sastry KS, Karpova Y, Kulik G (2006) Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 281: 27367-27377 (Pubitemid 44401764)
17. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H (2004) Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109: 182-188 (Pubitemid 38240918)
18. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK (2004) Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 64: 622-630 (Pubitemid 38120902)
19. Symon Z, Davis M, McGinn CJ, Zalupski MM, Lawrence TS (2002) Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 53: 140-145 (Pubitemid 34465817)
20. Thomadaki H, Scorilas A (2006) BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 43: 1-67 (Pubitemid 43379211)
21. Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247: 35-88
22. Workman HC, Sweeney C, Carraway III KL (2009) The membrane Mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 69: 2845-2852
23. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291